Novel treatment strategies and drugs in development for cryptosporidiosis

Miguel A. Chavez, A. Clinton White

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Cryptosporidium is a protozoan pathogen that can cause diarrheal disease in healthy and immunosuppressed individuals, worldwide. Recent studies have highlighted the impact of cryptosporidiosis on children in resource-limited countries. Nitazoxanide is the only Food and Drug Administration approved treatment, but it is not consistently effective therapy for cryptosporidiosis in the most vulnerable populations. Areas covered: This review focused on recent published studies evaluating novel drugs and new compounds for the treatment of cryptosporidiosis. Expert commentary: Combinations of approved drugs have demonstrated some activity. Broad screens have demonstrated activity against Cryptosporidium for a number of available drugs, including statins and clofazimine, and the latter has advanced into clinical trials. Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) has been identified as an attractive target for treatment, and bumped kinase inhibitors have been developed which inhibit CDPK1 and are active against Cryptosporidium growth both in vitro and in vivo. Inhibition of Plasmodium lipid kinase PI(4)K8 of Cryptosporidium by KDU731 greatly reduced oocyst shedding and improved diarrhea in calves with limited effects on the human PI(4)K. Another novel potent inhibitor MMV665917 was efficacious in mouse models with cidal activity against Cryptosporidium. Additional compounds have proved active in vitro. So far, only clofazimine has entered human trials.

Original languageEnglish (US)
Pages (from-to)655-661
Number of pages7
JournalExpert Review of Anti-Infective Therapy
Volume16
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Cryptosporidiosis
Cryptosporidium
Clofazimine
Pharmaceutical Preparations
nitazoxanide
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1-Phosphatidylinositol 4-Kinase
Plasmodium
Oocysts
Vulnerable Populations
Drug Combinations
United States Food and Drug Administration
Diarrhea
Phosphotransferases
Clinical Trials
Lipids
Growth

Keywords

  • anticryptosporidial
  • compound
  • cryptosporidiosis
  • Cryptosporidium
  • drugs
  • treatment

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Novel treatment strategies and drugs in development for cryptosporidiosis. / Chavez, Miguel A.; White, A. Clinton.

In: Expert Review of Anti-Infective Therapy, Vol. 16, No. 8, 03.08.2018, p. 655-661.

Research output: Contribution to journalReview article

@article{b89b7155095c45fe81e0e58ff30036ef,
title = "Novel treatment strategies and drugs in development for cryptosporidiosis",
abstract = "Introduction: Cryptosporidium is a protozoan pathogen that can cause diarrheal disease in healthy and immunosuppressed individuals, worldwide. Recent studies have highlighted the impact of cryptosporidiosis on children in resource-limited countries. Nitazoxanide is the only Food and Drug Administration approved treatment, but it is not consistently effective therapy for cryptosporidiosis in the most vulnerable populations. Areas covered: This review focused on recent published studies evaluating novel drugs and new compounds for the treatment of cryptosporidiosis. Expert commentary: Combinations of approved drugs have demonstrated some activity. Broad screens have demonstrated activity against Cryptosporidium for a number of available drugs, including statins and clofazimine, and the latter has advanced into clinical trials. Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) has been identified as an attractive target for treatment, and bumped kinase inhibitors have been developed which inhibit CDPK1 and are active against Cryptosporidium growth both in vitro and in vivo. Inhibition of Plasmodium lipid kinase PI(4)K8 of Cryptosporidium by KDU731 greatly reduced oocyst shedding and improved diarrhea in calves with limited effects on the human PI(4)K. Another novel potent inhibitor MMV665917 was efficacious in mouse models with cidal activity against Cryptosporidium. Additional compounds have proved active in vitro. So far, only clofazimine has entered human trials.",
keywords = "anticryptosporidial, compound, cryptosporidiosis, Cryptosporidium, drugs, treatment",
author = "Chavez, {Miguel A.} and White, {A. Clinton}",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/14787210.2018.1500457",
language = "English (US)",
volume = "16",
pages = "655--661",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Novel treatment strategies and drugs in development for cryptosporidiosis

AU - Chavez, Miguel A.

AU - White, A. Clinton

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: Cryptosporidium is a protozoan pathogen that can cause diarrheal disease in healthy and immunosuppressed individuals, worldwide. Recent studies have highlighted the impact of cryptosporidiosis on children in resource-limited countries. Nitazoxanide is the only Food and Drug Administration approved treatment, but it is not consistently effective therapy for cryptosporidiosis in the most vulnerable populations. Areas covered: This review focused on recent published studies evaluating novel drugs and new compounds for the treatment of cryptosporidiosis. Expert commentary: Combinations of approved drugs have demonstrated some activity. Broad screens have demonstrated activity against Cryptosporidium for a number of available drugs, including statins and clofazimine, and the latter has advanced into clinical trials. Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) has been identified as an attractive target for treatment, and bumped kinase inhibitors have been developed which inhibit CDPK1 and are active against Cryptosporidium growth both in vitro and in vivo. Inhibition of Plasmodium lipid kinase PI(4)K8 of Cryptosporidium by KDU731 greatly reduced oocyst shedding and improved diarrhea in calves with limited effects on the human PI(4)K. Another novel potent inhibitor MMV665917 was efficacious in mouse models with cidal activity against Cryptosporidium. Additional compounds have proved active in vitro. So far, only clofazimine has entered human trials.

AB - Introduction: Cryptosporidium is a protozoan pathogen that can cause diarrheal disease in healthy and immunosuppressed individuals, worldwide. Recent studies have highlighted the impact of cryptosporidiosis on children in resource-limited countries. Nitazoxanide is the only Food and Drug Administration approved treatment, but it is not consistently effective therapy for cryptosporidiosis in the most vulnerable populations. Areas covered: This review focused on recent published studies evaluating novel drugs and new compounds for the treatment of cryptosporidiosis. Expert commentary: Combinations of approved drugs have demonstrated some activity. Broad screens have demonstrated activity against Cryptosporidium for a number of available drugs, including statins and clofazimine, and the latter has advanced into clinical trials. Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) has been identified as an attractive target for treatment, and bumped kinase inhibitors have been developed which inhibit CDPK1 and are active against Cryptosporidium growth both in vitro and in vivo. Inhibition of Plasmodium lipid kinase PI(4)K8 of Cryptosporidium by KDU731 greatly reduced oocyst shedding and improved diarrhea in calves with limited effects on the human PI(4)K. Another novel potent inhibitor MMV665917 was efficacious in mouse models with cidal activity against Cryptosporidium. Additional compounds have proved active in vitro. So far, only clofazimine has entered human trials.

KW - anticryptosporidial

KW - compound

KW - cryptosporidiosis

KW - Cryptosporidium

KW - drugs

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85051708878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051708878&partnerID=8YFLogxK

U2 - 10.1080/14787210.2018.1500457

DO - 10.1080/14787210.2018.1500457

M3 - Review article

VL - 16

SP - 655

EP - 661

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 8

ER -